Contact lens with sustained release property

Abstract

A contact lens with sustained-release property is provided. The contact lens includes a polymer, pseudorotaxane embedded in the polymer, and a stabilizer embedded in the pseudorotaxane. The polymer is polymerized by monomer materials. The monomer materials include ethyl methacrylate, ethylene glycol dimethacrylate, methacrylic acid, 2-hydroxyethyl methacrylate, or a combination thereof. The stabilizer includes surfactant, amino acid with a polar side chain, oligopeptide containing at least one amino acid with a polar side chain, purine or its derivative, or a combination thereof.

What is claimed is: 
     
         1 . A contact lens with a sustained-release property, comprising:
 a polymer, polymerized by monomer materials, wherein the monomer materials comprise ethyl methacrylate, ethylene glycol dimethacrylate, methacrylic acid, 2-hydroxyethyl methacrylate, or a combination thereof;   pseudorotaxane, embedded in the polymer; and   a stabilizer, embedded in the pseudorotaxane, wherein the stabilizer comprises surfactants, amino acids with a polar side chain, oligopeptides containing at least one amino acid with a polar side chain, purine or its derivatives, or a combination thereof.   
     
     
         2 . The contact lens with a sustained-release property as claimed in  claim 1 , wherein the pseudorotaxane is composed of cyclodextrin and polyethylene glycol. 
     
     
         3 . The contact lens with a sustained-release property as claimed in  claim 2 , wherein the cyclodextrin comprises α-cyclodextrin, β-cyclodextrin, γ-cyclodextrin, hydroxypropyl-alpha-cyclodextrin, hydroxypropyl-beta-cyclodextrin, hydroxypropyl-gamma-cyclodextrin, sulfobutyl-beta-cyclodextrin, or a combination thereof. 
     
     
         4 . The contact lens with a sustained-release property as claimed in  claim 2 , wherein the polyethylene glycol has an average molecular weight ranging between 2,000 and 20,000. 
     
     
         5 . The contact lens with a sustained-release property as claimed in  claim 2 , wherein the cyclodextrin and the polyethylene glycol have a weight ratio ranging between 0.5:1 and 500:1. 
     
     
         6 . The contact lens with a sustained-release property as claimed in  claim 1 , wherein the pseudorotaxane and the polymer have a weight ratio ranging between 1:4 and 1:200. 
     
     
         7 . The contact lens with a sustained-release property as claimed in  claim 1 , wherein the stabilizer and the pseudorotaxane have a weight ratio ranging between 1:1 and 1:20. 
     
     
         8 . The contact lens with a sustained-release property as claimed in  claim 1 , further comprising an active ingredient embedded in the pseudorotaxane. 
     
     
         9 . The contact lens with a sustained-release property as claimed in  claim 8 , wherein the active ingredient and the pseudorotaxane have a weight ratio ranging between 1:0.1 and 1:40,000. 
     
     
         10 . The contact lens with a sustained-release property as claimed in  claim 8 , wherein the active ingredient in the contact lens has a content ranging between 0.1 μg/lens and 1,000 μg/lens. 
     
     
         11 . The contact lens with a sustained-release property as claimed in  claim 8 , wherein the active ingredient comprises menthol, steroids or their derivatives, antibiotics, tyrosine kinase inhibitors, or a combination thereof. 
     
     
         12 . The contact lens with a sustained-release property as claimed in  claim 1 , wherein the contact lens is further placed in a preservation solution. 
     
     
         13 . The contact lens with a sustained-release property as claimed in  claim 12 , wherein the preservation solution provides the stabilizer. 
     
     
         14 . A contact lens used for sustained release of drugs, comprising:
 a polymer, polymerized by monomer materials, wherein the monomer materials comprise ethyl methacrylate, ethylene glycol dimethacrylate, methacrylic acid, 2-hydroxyethyl methacrylate, or a combination thereof;   pseudorotaxane, embedded in the polymer; and   a stabilizer, embedded in the pseudorotaxane, wherein the stabilizer comprises surfactants, amino acids with a polar side chain, oligopeptides containing at least one amino acid with a polar side chain, purine or its derivatives, or a combination thereof.